Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 166.21M shares rose 3.4% year over year, in line with the +3.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.4% toward the trailing-twelve-month pace of +3.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
166.21M+0.5% QoQ
Last fiscal yearDec 2025
160M+7.0% YoY
LTMSep 2026
164.62M+3.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%——
1 year+7.0%——
3-year CAGR+4.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
160M USD
Year-over-year change
+7.0%
4-year CAGR
+3.2%

Weighted Avg Shares vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's LTM Sep 2026 weighted avg shares of 164.62M shares is the 3rd highest of the 9 companies compared; the peer median is 121.33M shares.
  • Its year-over-year change of +3.4% is the 5th highest of 9, against a peer median of +4.1%.
  • Over three fiscal years its annual growth of +4.1% compares with a peer median of +4.8%.
IONS Competitors Peer median
Weighted Avg Shares for IONS and competitors
Company Period LTM YoY 3-year CAGR
BBIOBridgeBio Pharma, Inc.LTM Jun 2026194.58M +2.6%+10.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026192.71M +0.7%+1.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
BIIBBiogen Inc.LTM Jun 2026147.05M +0.9%+0.3%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026132.45M +2.6%+2.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026102.01M +6.4%+6.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
Peer median (excluding IONS) 121.33M+4.1%+4.8%

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue810.46M587.37M787.65M705.14M944M
Cost of Revenue10.84M14.12M9.13M11.22M16M
Gross Profit799.61M573.25M778.51M693.92M928M
Gross Margin98.7%97.6%98.8%98.4%98.3%
Research & Development643M833M899.63M901.53M916M
Selling, General & Admin170.9M150.3M232.6M267.5M394M
Operating Expenses829.8M983.44M1.13B1.17B1.31B
Depreciation & Amortization19.56M22.11M22.5M21.99M22.69M
EBITDA(5.19M)(227.76M)(235.87M)(353.72M)(284.31M)
EBITDA Margin-0.6%-38.8%-29.9%-50.2%-30.1%
Operating Income(30.19M)(410.19M)(353.73M)(475.08M)(382M)
Operating Margin-3.7%-69.8%-44.9%-67.4%-40.5%
Interest Income10.04M25.33M89.04M107.02M97.77M
Interest Expense9.35M8.12M81.46M90.45M90.54M
Other Income / Expenses1.04M152.21M19.77M15.01M2M
Income Before Tax(29.15M)(257.99M)(333.97M)(460.07M)(380M)
Pre-Tax Margin-3.6%-43.9%-42.4%-65.2%-40.3%
Income Tax Expense(551K)11.74M32.32M(6.17M)1M
Net Income(28.6M)(269.72M)(366.29M)(453.9M)(381M)
Net Margin-3.5%-45.9%-46.5%-64.4%-40.4%
EPS (Basic)(0.20)(1.90)(2.56)(3.04)(2.38)
EPS (Diluted)(0.20)(1.90)(2.56)(3.04)(2.38)
Weighted Avg Shares141.02M141.85M143M149.51M160M
Weighted Avg Shares (Diluted)141.02M141.85M143.19M149.51M160M

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.